Scancell’s late-stage push for iSCIB1+ reframes the risk calculus in advanced melanoma trials
FDA clears Scancell’s iSCIB1+ for Phase 3 testing in advanced melanoma. Discover what this means for immunotherapy risk, trial design, and competition.
PharmaJet’s needle-free system to power Scancell’s melanoma Phase 3 after strong DNA therapy data
PharmaJet’s needle-free device will deliver Scancell’s DNA immunotherapy in a Phase 3 melanoma trial. Find out what this means for the future of cancer vaccines.